CSIMarket



Celgene Corp  (CELG)
Other Ticker:  
 
 


Celgene Corp Segments

 
REVLIMID
   62.85 % of total Revenue
THALOMID
   1.95 % of total Revenue
ABRAXANE
   9.94 % of total Revenue
VIDAZA
   6.38 % of total Revenue
Other
   0.12 % of total Revenue
Total product sales
   100 % of total Revenue
ISTODAX
   0.75 % of total Revenue
POMALYST, IMNOVID
   11.09 % of total Revenue
azacitidine injection
   0.92 % of total Revenue
 

Business Segments (Sep. 30, 2015)
Revenues
(in millions $)
III. Quarter
%
(of total Revenues)
(Sep. 30, 2015)
Income
(in millions $)
III. Quarter
%
(Profit Margin)
REVLIMID
1,453.50 62.85 % 0.00 -
THALOMID
45.10 1.95 % 0.00 -
ABRAXANE
229.90 9.94 % 0.00 -
VIDAZA
147.60 6.38 % 0.00 -
Other
2.70 0.12 % 0.00 -
Total product sales
2,312.60 100 % 0.00 -
ISTODAX
17.30 0.75 % 0.00 -
POMALYST, IMNOVID
256.50 11.09 % 0.00 -
azacitidine injection
21.30 0.92 % 0.00 -
Total
2,312.60 100 % 0.00 -

• View Income Statement • View Competition by Segment • View Annual Report

Growth rates by Segment (Sep. 30, 2015)
Y/Y Revenue
%
III. Quarter
Q/Q Revenue
%
(Sep. 30, 2015)
Y/Y Income
%
III. Quarter
Q/Q Income
%
REVLIMID
11.81 % 0.66 % - -
THALOMID
-13.1 % -5.85 % - -
ABRAXANE
8.34 % -5.86 % - -
VIDAZA
-6.46 % -2.96 % - -
Other
350 % 80 % - -
Total product sales
18.18 % 2.6 % - -
ISTODAX
10.19 % -3.35 % - -
POMALYST, IMNOVID
41.63 % 9.38 % - -
azacitidine injection
7.04 % -4.48 % - -
Total
16.67 % 2.6 % - -

• View Growth rates • View Competitors Segment Growth • View Market Share

To get more information on Celgene's REVLIMID, THALOMID, ABRAXANE, VIDAZA, Other, Total product sales, ISTODAX, POMALYST, IMNOVID, azacitidine injection, Total segment. Select each division with the arrow.

  Celgene's

Business Segments Description



REVLIMID(R) (LENALIDOMIDE): REVLIMID(R) is an oral immunomodulatory drug recently granted approval by the FDA for the treatment of patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities, or MDS, with the 5q chromosomal deletion. REVLIMID(R) is being distributed through contracted pharmacies under the RevAssist(sm) program, which is a proprietary risk-management distribution program tailored specifically for REVLIMID(R). The FDA based its decision to grant marketing approval on data from the open label Phase II trial (MDS-003) that evaluated REVLIMID(R) in transfusion-dependent patients with myelodysplastic syndromes with deletion 5q chromosomal abnormality.

THALOMID(R) (THALIDOMIDE): THALOMID(R), was approved by the FDA in July 1998 for the treatment of acute cutaneous manifestations of moderate to severe erythema nodosum leprosum, or ENL, an inflammatory complication of leprosy. Although leprosy is relatively rare in the United States, the disease afflicts millions worldwide. ENL occurs in about 30% of leprosy patients and is characterized by skin lesions, acute inflammation, fever and anorexia. While approved for the treatment of ENL, THALOMID(R) is widely prescribed off-label for treating multiple myeloma and other cancers. The FDA is currently reviewing our sNDA for THALOMID(R) in multiple myeloma and has set a Prescription Drug User Fee Act, or PDUFA, date of May 25, 2006.

Working with the FDA, we developed S.T.E.P.S.(R), or "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY," which is a proprietary strategic comprehensive education and risk-management distribution program with the objective of providing for the safe and appropriate use of THALOMID(R).

ALKERAN(R): In March 2003, we entered into a supply and distribution agreement with GlaxoSmithKline, or GSK, to distribute, promote and sell ALKERAN(R) (melphalan) in all dosage forms in the United States under the Celgene label. ALKERAN(R) is approved by the FDA for the palliative treatment of multiple myeloma and of carcinoma of the ovary. ALKERAN(R) use in combination with other therapies for the treatment of hematological diseases continues to grow, driven by clinical data reported at major medical conferences around the world. Under the terms of the agreement, we purchase ALKERAN(R) tablets and ALKERAN(R) for injection from GSK and distribute the products in the United States under the Celgene label. The agreement has been extended through March 31, 2009.

RITALIN(R) FAMILY OF DRUGS: We developed FOCALIN(TM), which is formulated by isolating the active d-isomer of methylphenidate using advanced single-isomer chemistry technology. Isomers are any of two or more chemical substances that are composed of the same elements in the same proportions but can differ in properties because of differences in the arrangement of atoms. FOCALIN(TM) provides favorable tolerability and dosing flexibility at half the dose of RITALIN(R). In April 2000, we licensed to Novartis the worldwide rights (excluding Canada) to FOCALIN(TM) and FOCALIN XR(TM), the extended release version, in exchange for milestone payments, a FOCALIN(TM) product supply agreement (whereby we supply FOCALIN(TM) exclusively to Novartis) and royalties on FOCALIN XR(TM) and the entire RITALIN(R) family of drugs including RITALIN(R), RITALIN LA(R) and RITALIN SR(R). We have retained the exclusive commercial rights to FOCALIN(TM) and FOCALIN XR(TM) for oncology-related disorders, such as chronic fatigue associated with chemotherapy. On November 15, 2001, FOCALIN(TM) was approved by the FDA for the treatment of attention deficit hyperactivity disorder, or ADHD, in children and adolescents. On May 27, 2005, FOCALIN XR(TM) was approved by the FDA for the treatment of ADHD in adults, adolescents and children.

ABRAXANE® was obtained in the acquisition of Abraxis in October 2010 and was approved by the FDA in the treatment of metastatic breast cancer.

   

Sales by Geography Competition By Business Segments Company Profile
       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

BTCS's Profile

Stock Price

BTCS's Financials

Business Description

Fundamentals

Charts & Quotes

BTCS's News

Suppliers

BTCS's Competitors

Customers & Markets

Economic Indicators

BTCS's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071